Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the …
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy Read More